In a recent announcement, Apeloa Pharmaceutical Co.,Ltd. (SHE: 000739) disclosed that its subsidiary, Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Sodium Valproate Sustained-Release Tablets (I) from the National Medical Products Administration.
The product has been approved for market as a Category 4 chemical drug, which qualifies it as passing the generic drug consistency evaluation.
This medication is primarily indicated for the treatment of generalized epilepsies, including absence seizures, myoclonic seizures, tonic-clonic seizures, atonic seizures, and mixed seizure types, as well as specific syndromes such as West syndrome and Lennox-Gastaut syndrome.
It is also used for treating partial-onset seizures and is approved for managing manic episodes associated with bipolar disorder.
Market data indicates that the domestic market for Sodium Valproate Sustained-Release Tablets in 2025 is estimated at approximately 580 million tablets, with a corresponding sales value of around 1.05 billion yuan.
Comments